Pall ForteBio Introduces Off-the-Shelf Dip and Read Anti-CHO HCP Detection Kit to Accelerate Drug Development
Pall ForteBio, a division of Pall Corp. has announced commercial availability of a new Dip and Read Anti-CHO (Chinese hamster ovary) Host Cell Protein (HCP) Detection Kit for quantitation of residual HCPs. Kit users benefit from faster time to results, enhanced range of detection and better assay precision, all of which accelerate the drug development timeline while improving safety and efficacy. The kit can also be applied in production phases to confirm reduction or removal of HCP, increasing efficiency and speed of production.
The kit combines the Pall ForteBio Octet platform for rapid high-throughput protein analysis with the broad HCP recognition and sensitivity of the industry-standard Cygnus 3G anti-CHO HCP antibody. The high-precision assays have 5–10% CVs, and the design allows the analysis to be done, without supervision, in 65–90 minutes.
“The commonly used ELISA HCP analytical method can require up to overnight analysis and must be monitored. Our new Dip and Read high-precision assay kit, in combination with the Octet HTX system, is hands-free, and only takes around an hour to analyse 96 samples with detection sensitivity as low as 0.5 ng/mL,” said Yves Baratelli, President of Pall Life Sciences. “This translates into a dramatic advance in the user’s process, and a drastic reduction in their time and capital investment from development through to production.”
As the most commonly used mammalian hosts for industrial production of recombinant protein therapeutics, CHO cells often leave behind contaminating HCPs. The residuals can substantially decrease the efficacy of a drug product, or even cause immunogenic reactions in patients. Therefore, detection and reduction of residual HCP contaminants is critical for drug safety and qualification.
“The HCP detection kit complements the use of Octet systems for protein titer measurement and residual protein A contaminant detection in bioprocessing. So far the feedback from customers has been exceptional. More than six key customers from large biopharmaceutical companies have completed beta testing with the product,” Robert Wicke, Sr. VP for Instrumentation R&D at Pall ForteBio, said. “It is a great complement to our full detection line, all supported by Octet instruments.”
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance